Sixth Amendment to Patent License Agreement, effective as of August 24, 2017, by and between the Registrant and the Regents of the University of Michigan
Exhibit 10.23
***Text Omitted and Filed Separately with the Securities and Exchange Commission.
Confidential Treatment Requested Under
17 C.F.R. Sections 200.80(b)(4) and 240.24b-2
VIA CERTIFIED MAIL
August 24, 2017
The Regents of the University of Michigan
Office of Research and Sponsored Projects
3003 S. State St. Room 1070
Ann Arbor, MI 48109-1274
Attn: Anthony L. Neilsen, J.D.
| RE: | Research Agreement between Kura Oncology, Inc. (“Kura”) and The Regents of the University of Michigan (the “University”) dated February 15, 2015 (the “Research Agreement”) |
| (Amendment 6 to the Patent License Agreement dated December 22, 2014) |
Dear Anthony:
Pursuant to Section 8.2 of the Research Agreement, we hereby give notice of the exercise by Kura of its option to obtain an exclusive royalty-bearing license to the University’s interest in the patent application numbered […***…]. Effective upon this notice, the Patent License Agreement between the University and Kura is deemed amended (Amendment 6) to add the above-referenced patent application to subsection (ii)(a) of the definition of PATENT RIGHTS under such agreement.
Please let me know if you have any questions.
Sincerely,
/s/ Annette North
Annette North
SVP, General Counsel
cc: Ed Pagani, Ph.D., Associate Director,
University of Michigan
***Confidential Treatment Requested
3033 Science Park Road, Suite 220, San Diego, CA 92121
